Market Context — Why This Technology, Why Now

Rising global healthcare costs and the increasing prevalence of chronic and intractable diseases are pressuring pharmaceutical companies to innovate. This technology offers a targeted approach to interstitial lung diseases, a market projected to reach ~$6.5B globally (AI est.) with a 6.5% CAGR, addressing unmet needs. The demand for personalized medicine and early diagnostic markers is also accelerating, making integrated diagnostic-therapeutic solutions highly valuable for market differentiation and patient outcomes.

Key Competitive Advantages
01

Offers a novel LRG-targeted therapeutic approach for acute-stage diseases by focusing on cell migration inhibition, a mechanism difficult to address with existing treatments.

02

Provides an integrated diagnostic and therapeutic solution by utilizing LRG as a disease activity marker, enabling treatment monitoring and prognostic evaluation, contributing to personalized medicine.

03

Ensures a strong IP foundation for market advantage with stable patent rights, validated against 8 prior art documents, guaranteeing differentiation for licensees.

Market Opportunity
Intractable Disease Therapeutics Market
$1B globally (AI est.)
High unmet needs and limitations of existing treatments create significant demand for novel therapeutics, potentially driving market expansion.
Global pharmaceutical companies focusing on rare diseases Biotech firms developing novel anti-inflammatory drugs Contract Research Organizations (CROs) for clinical trials
Personalized Medicine & Diagnostics Market
$330M globally (AI est.)
Leveraging LRG as a biomarker enables optimal treatment selection and efficacy monitoring for individual patients, accelerating market growth.
Diagnostic kit manufacturers Precision medicine developers Medical device companies with biomarker platforms
Drug Discovery & Regenerative Medicine Market
$650M globally (AI est.)
Elucidating LRG's mechanism of action suggests broader applications in other inflammatory and tissue repair-related diseases, positioning it as a novel drug target.
Large pharmaceutical R&D divisions Academic research institutions seeking drug targets Regenerative medicine startups
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent establishes robust, low-invalidation-risk rights, optimized through dialogue with examiners and clearing stringent examination standards. It covers a broad range of claims, including the use of LRG inhibitors, screening methods, and their application as diagnostic markers, providing a strong foundation for licensees' business development.

Competitive White Space

White space could include novel drug delivery systems for LRG inhibitors, advanced AI-driven diagnostic algorithms for LRG markers, or integration with broader personalized health platforms beyond specific disease activity assessment.

Economic Impact
~$65M/year estimated economic impact per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

The estimated domestic market for interstitial lung diseases is ~$1B (AI est.) annually. By introducing new therapeutics and diagnostics based on this technology, capturing a 5% market share through switches from existing treatments and new patient acquisition could generate an additional ~$50M (AI est.) in annual sales. Furthermore, considering the potential for reduced clinical trial periods, an estimated 10% reduction in development costs (~$13.5M (AI est.)) could be achieved, leading to a total economic impact of ~$65M (AI est.) annually.

Speed to Market
3× faster than in-house development
While novel drug discovery typically requires over 5 years for basic research and preclinical trials, this technology's clear LRG-targeted mechanism of action means much of the foundational research is already established by the patent. This significantly accelerates the transition to preclinical and clinical trials for licensees. With the mechanism of action and screening methods already defined, development time could be effectively reduced by approximately 3.5 years.
Competitive Positioning

X: Innovativeness of Therapeutic Effect
Y: Integration of Diagnosis & Treatment

Business Models & Applications
💊 New Drug Development & Sales Business
Develop and sell novel drugs based on LRG inhibitors to healthcare institutions, potentially achieving high profitability in the intractable disease sector.
🔬 Diagnostic Kit Provision Business
Develop diagnostic kits to measure LRG for disease activity assessment and prognostic evaluation. Establish a market for early diagnosis, combining medical contribution with business growth.
🤝 Collaborative Research & Licensing Business
Promote partnerships with pharmaceutical companies and research institutions to further elucidate LRG mechanisms and explore applications in other diseases. This could drive technology dissemination and new value creation.
Adjacent Application Opportunities
🦠 Inflammatory Bowel Disease
Novel Treatment for Intestinal Inflammation
LRG is involved in inflammation and cell migration, suggesting potential application in repairing intestinal epithelial damage and suppressing inflammation in inflammatory bowel diseases like Crohn's disease and ulcerative colitis. Local administration of LRG inhibitors could enable the development of effective treatments with reduced side effects.
🦴 Autoimmune Diseases
Slowing Rheumatoid Arthritis Progression
In rheumatoid arthritis, abnormal proliferation of synovial cells and inflammation drive disease progression. Applying LRG's cell migration regulation mechanism could inhibit inflammatory cell infiltration in synovial inflammation, offering a new therapeutic option.
🩹 Skin Conditions
Improving Wound Healing & Skin Inflammation
Cell migration also plays a crucial role in skin wound healing and inflammatory skin conditions such as atopic dermatitis. Developing LRG inhibitors as topical agents could suppress skin inflammation and promote normal tissue repair, offering a potential therapeutic application.
Integration Roadmap — Estimated 28-Month Deployment
Technology Evaluation & Preclinical Planning
Duration: 5 months
Detailed evaluation of the technology's mechanism of action and planning for proof-of-concept studies using animal models to concretize the development roadmap.
Preclinical Trials & Development
Duration: 15 months
Verify the safety and efficacy of LRG inhibitors through non-clinical trials, gather data for IND (Investigational New Drug) application, and advance formulation research.
Clinical Trial Preparation & Application
Duration: 8 months
Prepare clinical trial protocols, manufacture investigational drugs, and prepare for regulatory submissions, aiming to initiate human clinical trials and pave the way for market introduction.
Technical Feasibility
This technology, based on a clear target mechanism of LRG functional inhibition, exhibits high compatibility with existing biopharmaceutical development platforms. The patent claims explicitly mention LRG expression or function inhibitors and LRG-binding reagents, whose development is achievable using standard molecular biology techniques and antibody drug development technologies. This offers technical feasibility by minimizing new capital investment and maximizing the utilization of existing drug discovery research infrastructure.
Success Scenario
Adopting this technology could expand treatment options for acute interstitial lung diseases, potentially leading to significantly improved patient prognoses. When combined with LRG-based diagnostics, the precision of personalized medicine could be enhanced, maximizing treatment efficacy. This is estimated to enable licensees to establish market leadership in intractable disease areas and expand annual revenues by several million dollars.
Patent Record
APPLICATION NO.
特願2020-030643
REGISTRATION NO.
6852926
FILING DATE
2020/02/26
GRANT DATE
2021/03/15
EXPIRATION DATE
2040/02/26
PATENT HOLDER
学校法人岩手医科大学
Examination History
2020年02月26日
出願審査請求書
2020年12月21日
拒絶理由通知書
2021年01月12日
意見書
2021年01月12日
手続補正書（自発・内容）
2021年02月02日
特許査定